Mucus Phosphatidylcholine / Delayed-Release PC Barrier Repair in UC
Main digest: UC Causal Mechanism Digest 006 — Mucus Phosphatidylcholine and Delayed-Release PC
Working model
low mucus phosphatidylcholine / impaired PC transport
↓
weak hydrophobic mucus barrier
↓
bacteria and microbial products approach epithelium more easily
↓
rectal/distal barrier threshold is crossed under added stressors
↓
mucus → constipation/tenesmus/contact time → blood/pain/calprotectinWhy it matters for Paul
This mechanism matches several high-priority observations:
- symptoms often begin with mucus;
- disease is proctitis/distal-focused;
- constipation/contact time appears to precede bleeding;
- dairy/wheat/sleep/stress may cross a barrier threshold;
- Paul has noted PEMT/PC-deficiency concerns and has researched PC products.
Key insight
Mucus phosphatidylcholine is one of the best-fitting causal branches, but delivery and formulation are everything.
Generic oral lecithin/systemic PC ≠ proven colonic mucus PC restoration.The right question is:
Which PC species/formulation reaches the colon/rectal mucus, in whom, at what dose, and with what objective endpoint?Evidence summary
Mechanistic evidence
- PC may form a hydrophobic lamellar layer in colonic mucus.
- UC rectal mucus PC has been reported to be about 70% lower than Crohn’s/controls, independent of disease activity.
- Mucus PC may thin toward the rectum, potentially explaining proctitis-first vulnerability.
- Bacterial ectophospholipases may further degrade mucus PC.
- PC34:1/lipidomics work suggests specific PC species and biosynthetic pathways such as PEMT/PCYT1α may matter.
Clinical evidence
Hopeful signals:
- Early retarded/delayed-release PC RCTs showed clinical, endoscopic, histologic, and steroid-withdrawal benefits.
- A 2021 meta-analysis of 3 monocenter RCTs/160 patients reported large positive odds ratios and placebo-like adverse events.
Tempering signals:
- 2024 multicenter LT-02 induction trials failed the primary endpoint; PCG-2 was stopped for futility.
- PROTECT-3 registry entry was terminated because LT-02 did not appear to help induce remission.
- LT-02 was safe/well-tolerated, and maintenance signal may need further study, but induction efficacy was not proven.
Formulation questions
Important distinctions:
| Category | Why it matters |
|---|---|
| Generic lecithin | Likely absorbed before colon; not equivalent to studied delayed-release PC. |
| Systemic PC supplements | May support systemic/liver/membrane PC status but may not restore colonic mucus PC. |
| 30% PC delayed intestinal-release lecithin | Positive early RCT/meta-analysis signal; research-line concentrated. |
| >94% modified-release LT-02 | Larger/multicenter induction trial failed; safe but not proven for induction. |
| Saturated PC / product variants | Interesting but evidence depends on exact formulation and delivery. |
| Rectal/local PC delivery | Conceptually attractive for proctitis, but needs evidence search. |
What would make this personally testable?
Research/tracking endpoints if discussed with clinician:
- mucus frequency/severity;
- blood episodes;
- stool form and incomplete evacuation/contact-time pattern;
- urgency/tenesmus/rectal pain;
- fecal calprotectin;
- CRP/ESR;
- sleep status and dairy/wheat exposure;
- scope/endoscopic/histologic markers if clinically indicated;
- lipid/ALP markers if PC branch overlaps gut-liver-lipid axis.
Clinician questions
- Is PC supplementation appropriate/safe in Paul’s context?
- Do soy/egg-derived PC products raise allergy/intolerance concerns?
- Are there liver/bile/lipid considerations given ALP/cholesterol patterns?
- Are any current products actually comparable to studied delayed-release PC formulations?
- Is a rectal/local barrier-support strategy more relevant for proctitis?
- Can PEMT/PC deficiency be interpreted clinically, or only as research context?